Insider purchase and holdings
Thomas Joeseph Carrico, who serves as Chief Research Officer, Chief Commercial Officer and Chief Product Officer at Neuraxis, INC (NASDAQ: NRXS), filed a Form 4 with the Securities and Exchange Commission showing the acquisition of 667 shares of the companys common stock. The purchase was executed at $1.96 per share on April 1, 2026, for a total reported outlay of $1,307. After the transaction, Carrico is recorded as directly owning 331,903 shares of Neuraxis, INC.
Market performance since the buy
Following Carricos purchase, the shares have climbed to $7.25, a significant increase compared with his $1.96 execution price. Data cited from InvestingPro indicates that NRXS has returned 272% over the past year. At the time of the referenced valuation, the stock was trading slightly above its Fair Value assessment of $7.06.
Quarterly financials
Neuraxis disclosed fourth-quarter 2025 results that showed top-line growth alongside continued losses. Revenue for the period rose 27% year over year to $968,000. Despite higher revenue, the company reported a net loss of $1.7 million for the quarter, compared with a $1.5 million loss in the same quarter the prior year. Management attributed a 100 basis-point decline in gross margin to inventory challenges and the launch of a lower-margin product.
Context for investors
The filing and the financial update present a mixed picture: an insider purchase at a modest total dollar value and a material increase in the share price since that transaction, paired with quarter-to-quarter operational and margin pressures that have contributed to continuing quarterly losses. The companys revenue growth and the insider participation are factual touchpoints; the reported margin compression, inventory matters and product mix change are the explicit drivers called out by the company for deteriorating gross margin in the quarter.
What remains unclear
The available disclosures do not provide further detail about the nature or duration of the inventory challenges, the expected margin trajectory for the introduced product, or managements plans to address the widening loss. The companys stock movements beyond the cited surge to $7.25 are noted but specifics of intraday or subsequent trading are not detailed in the filings discussed.
Bottom line
Carricos April 1, 2026 purchase is a recorded insider transaction of 667 shares at $1.96, increasing his direct holdings to 331,903 shares. Neuraxis reported stronger revenue in Q4 2025 but also a larger net loss and a one-percentage-point decline in gross margin, attributable in company disclosures to inventory issues and a lower-margin product introduction. Investors evaluating NRXS should weigh the insider purchase and strong year-to-date share performance against the firms ongoing losses and margin pressures.